This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate
by Zacks Equity Research
Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.
REGNPositive Net Change RHHBYPositive Net Change DVAXPositive Net Change TRDAPositive Net Change
biotechnology biotechs
Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study
by Zacks Equity Research
After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.
AZNNegative Net Change NVONegative Net Change MRKPositive Net Change CTMXPositive Net Change
biotechs medical pharmaceuticals vaccines
Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474
by Zacks Equity Research
Kymera (KYMR) receives a $15 million milestone payment from Sanofi as dosing begins in a phase II study evaluating KT-474 for treating atopic dermatitis. Shares rise on the same.
SNYPositive Net Change PBYINegative Net Change KYMRPositive Net Change TRDAPositive Net Change
biotechs
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up
by Zacks Equity Research
Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
RHHBYPositive Net Change SRPTPositive Net Change PTCTNegative Net Change SLDBNegative Net Change
biotechnology biotechs medical pharmaceuticals
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
by Zacks Equity Research
Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%.
BCRXNo Net Change NVONegative Net Change IONSPositive Net Change PHVSPositive Net Change
biotechs medical
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
by Zacks Equity Research
Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
REGNPositive Net Change SNYPositive Net Change AZNNegative Net Change NVONegative Net Change
biotechs medical pharmaceuticals vaccines
Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study
by Zacks Equity Research
Century (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%.
AGENPositive Net Change PBYINegative Net Change ADMANegative Net Change IPSCPositive Net Change
biotechnology biotechs gene-editing gene-therapy immuno-therapy medical pharmaceuticals
Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene
by Zacks Equity Research
Syros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia.
PBYINegative Net Change AQSTPositive Net Change TRDAPositive Net Change
biotechs
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
by Zacks Equity Research
Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.
BMYPositive Net Change EXELPositive Net Change EYPTPositive Net Change RCUSPositive Net Change PHVSPositive Net Change
biotechnology biotechs
Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALS
by Zacks Equity Research
Dr. Reddy's (RDY) enters into a licensing agreement with Coya Therapeutics to develop and commercialize the latter's ALS investigational combination therapy, COYA 302.
RDYPositive Net Change AGENPositive Net Change PBYINegative Net Change COYANegative Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
by Zacks Equity Research
AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.
NVONegative Net Change IMGNPositive Net Change ABBVNegative Net Change CEREPositive Net Change
biotechs
Travere (TVTX) Up on Latest Portfolio Updates & Reorganization
by Zacks Equity Research
Travere (TVTX) to submit an sNDA to the FDA to convert the accelerated approval for Filspari to full approval for IgAN in first-quarter 2024. The company is implementing a strategic reorganization to cut costs. Stock rises.
PBYINegative Net Change TVTXPositive Net Change AVTXPositive Net Change TRDAPositive Net Change
biotechs
ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA
by Zacks Equity Research
The FDA grants priority review to ImmunoGen's (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.
IMGNPositive Net Change ABBVNegative Net Change HARPNegative Net Change AVTXPositive Net Change
biotechs
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
by Zacks Equity Research
Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.
PFEPositive Net Change NVONegative Net Change CTMXPositive Net Change ARVNPositive Net Change
biotechs medical pharmaceuticals
Bristol Myers' (BMY) Opdivo sBLA Gets FDA's Priority Review
by Zacks Equity Research
Bristol Myers (BMY) announces that the FDA has accepted its sBLA for Opdivo to treat first-line adult patients with unresectable or metastatic bladder cancer under priority review.
BMYPositive Net Change AGENPositive Net Change PBYINegative Net Change ADMANegative Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study
by Zacks Equity Research
Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.
BMYPositive Net Change MRKPositive Net Change EXELPositive Net Change RCUSPositive Net Change
biotechnology biotechs pharmaceuticals
Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
by Zacks Equity Research
Roche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation achieves its primary goal.
RHHBYPositive Net Change DVAXPositive Net Change PFEPositive Net Change TRDAPositive Net Change
biotechs pharmaceuticals
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
by Zacks Equity Research
Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.
NVONegative Net Change PBYINegative Net Change CTMXPositive Net Change ATHENegative Net Change
biotechs medical
CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline
by Zacks Equity Research
Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.
NVONegative Net Change VRTXNegative Net Change CTMXPositive Net Change CRSPPositive Net Change
biotechs crispr medical pharmaceuticals
EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data
by Zacks Equity Research
EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.
REGNPositive Net Change BAYRYNegative Net Change EYPTPositive Net Change KODPositive Net Change
biotechnology biotechs medical pharmaceuticals
Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug
by Zacks Equity Research
The FDA accepts Vanda's (VNDA) new drug application ("NDA") for tradipitant for treating the symptoms of gastroparesis. The company's shares rise in after-hours trading.
PBYINegative Net Change VNDANegative Net Change CTMXPositive Net Change TRDAPositive Net Change
biotechs
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
by Zacks Equity Research
Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.
AZNNegative Net Change MRNAPositive Net Change IMTXPositive Net Change ABSIPositive Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.
LLYNegative Net Change PBYINegative Net Change CTMXPositive Net Change ACIUPositive Net Change
biotechs
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
by Zacks Equity Research
Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
AZNNegative Net Change JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study
by Zacks Equity Research
Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.
PFEPositive Net Change NVONegative Net Change LLYNegative Net Change ALTPositive Net Change
biotechnology biotechs medical pharmaceuticals